New Zealand markets open in 1 hour 33 minutes

Qiagen N.V. (QGEN)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
43.73+0.56 (+1.30%)
At close: 04:00PM EDT
45.60 +1.87 (+4.26%)
After hours: 05:36PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close43.17
Bid43.04 x 800
Ask44.47 x 800
Day's range43.55 - 43.85
52-week range34.74 - 47.70
Avg. volume1,002,385
Market cap9.701B
Beta (5Y monthly)0.42
PE ratio (TTM)28.77
Earnings dateN/A
Forward dividend & yield1.28 (2.94%)
Ex-dividend date30 Jan 2024
1y target estN/A
  • GlobeNewswire

    QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical device software for clinical decision support

    As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is approved for diagnostic use // Regulatory framework ensures greater patient protection, transparency of information, and traceability of data // Over 4 million NGS patient test cases for oncology and hereditary diseases worldwide processed with QIAGEN Clinical Insight InterpretVenlo, the Netherlands, May 14, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE

  • GlobeNewswire

    QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accurate results

    QIAstat-Dx Respiratory Panel Plus designed for accurate diagnosis of respiratory infections, enabling detection of co-infections // Panel generates results in about one hour with less than one minute of hands-on time; offers easy access to Ct values and amplification curves // QIAGEN working on expanding QIAstat-Dx testing menu in the U.S., with a Gastrointestinal Panel currently under FDA reviewGermantown, Maryland, and Venlo, the Netherlands, May 13, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN

  • GlobeNewswire

    QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

    Collaboration aims to create novel digital PCR assay to improve successful results in DNA analysis from human samples for use in forensics and human identification // DNA quantification enables law enforcement and forensic researchers to analyze a broader range of evidence more quickly, accurately and reliably // Collaboration strengthens QIAGEN’s leading position in human identification and forensicsVenlo, the Netherlands, and Washington, D.C., May 07, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGE